Lee, Ga Young Kim, Jong-Ho Choi, Ki Young Yoon, Hong Yeol Kim, Kwangmeyung Kwon, Ick Chan Choi, Kuiwon Lee, Byung-Heon Park, Jae Hyung Kim, In-San 2024-01-20T07:02:05Z 2024-01-20T07:02:05Z 2021-09-04 2015-06 0142-9612 https://pubs.kist.re.kr/handle/201004/125408 For the effective diagnosis and therapy of atherosclerosis, there is a pressing need to develop the carrier which can specifically deliver the agents to the pathological site. Since the representative hallmark of atherosclerosis in its pathogenic process is the over-expression of the receptors for hyaluronic acid (HA) such as stabilin-2 and CD44, we herein investigated the potential of HA nanoparticles (HA-NPs) as the carrier for active targeting atherosclerosis. From in vitro cellular uptake tests, it was revealed that HA-NPs were selectively taken up by the cells over-expressing stabilin-2 or CD44. On the other hand, the cellular uptake of HA-NPs was drastically reduced when the cells were pre-treated with excess amount of free HA, implying that HA-NPs were taken up by the receptor-mediated endocytosis. Following systemic administration of Cy5.5-labeled NPs into the ApoE-deficient mice as the animal model, the atherosclerotic legion was assessed at 24 post-injection by using the optical imaging system. Interestingly, the fluorescent signal of the atherosclerotic lesion by HA-NPs was much stronger than that of the normal aorta. Three dimensional z-stack images of an atherosclerotic plaque indicated the even distribution of HA-NPs in the atherosclerotic legion. It was demonstrated by immunohistochemistry that HA-NPs were co-localized with the HA receptors including stabilin-2 and CD44. In addition, the amount of HA-NPs, accumulated in the atherosclerotic lesion, was much higher than that of HGC-NPs, known to reach the atherosclerotic lesion by the passive targeting mechanism. Overall, it was evident that HA-NPs could effectively reach the atherosclerotic lesion via the active targeting mechanism after systemic administration, implying their high potential as the carrier for diagnosis and therapy of atherosclerosis. (C) 2015 Elsevier Ltd. All rights reserved. English ELSEVIER SCI LTD IN-VIVO DRUG-DELIVERY FEEDBACK LOOP CANCER RECEPTOR CD44 NANOCARRIERS INFLAMMATION MACROPHAGES DOXORUBICIN Hyaluronic acid nanoparticles for active targeting atherosclerosis Article 10.1016/j.biomaterials.2015.02.089 1 BIOMATERIALS, v.53, pp.341 - 348 BIOMATERIALS 53 341 348 scie scopus 000353929800032 2-s2.0-84927915334 Engineering, Biomedical Materials Science, Biomaterials Engineering Materials Science Article IN-VIVO DRUG-DELIVERY FEEDBACK LOOP CANCER RECEPTOR CD44 NANOCARRIERS INFLAMMATION MACROPHAGES DOXORUBICIN Hyaluronic acid Active targeting Atherosclerosis Nanoparticles